11 assets in Respiratory Tract Neoplasm

Therapeutic assets addressing Respiratory Tract Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Respiratory Tract Neoplasm	Fundación GECP	P3	BB (68)
Cis-Diamminedichloroplatinum Ii Respiratory Tract Neoplasm	Nanfang Hospital, Southern Medical University	P3	BB (64)
Adebrelimab Respiratory Tract Neoplasm	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Atezolizumab Respiratory Tract Neoplasm	Fundación GECP	P2	CCC (53)
Durvalumab Respiratory Tract Neoplasm	Fundación GECP	P2	CCC (53)
Etoposide Respiratory Tract Neoplasm	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Respiratory Tract Neoplasm	Fundación GECP	P2	CCC (53)
Tarlatamab Respiratory Tract Neoplasm	Fundación GECP	P2	CCC (51)
Blu-701 Respiratory Tract Neoplasm	Blueprint Medicines Corporation	P1	CC (43)
Osimertinib Respiratory Tract Neoplasm	Blueprint Medicines Corporation	P1	CC (43)
Pebezertinib Respiratory Tract Neoplasm	Blueprint Medicines Corporation	P1	CC (43)